Shareholders approved all proposed resolutionsPARIS, FRANCE / ACCESSWIRE / November 15, 2022 / Abivax SA (Euronext Paris: FR0012333284 – ABVX), a phase 3 clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held an ad hoc ordinary and extraordinary general meeting of shareholders on November 9…
Read More
About The Author
